ARGX Stock Recent News
ARGX LATEST HEADLINES
Argenx (ARGX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 9:00 a.m. PT.
argenx's (ARGX) phase III ADDRESS study, evaluating efgartigimod subcutaneous for treating pemphigus, fails to meet primary and secondary endpoints. Stock falls.
Immunovant unveiled promising results for a Graves' disease treatment on Thursday, helping IMVT stock reverse a recent downfall.
Shares of biotechnology specialist Argenx (NASDAQ: ARGX ) — which focuses on addressing severe autoimmune diseases – suffered a hefty decline on Wednesday following a clinical disappointment. Its Phase 3 study for a disease that causes skin blisters failed to meet its primary and secondary objectives.
Argenx SE (NASDAQ: ARGX) says a late-stage trial of its candidate drug for an autoimmune condition failed to meet the primary or secondary endpoints. Its shares are down 25% at writing.
Argenx stock ARGX, -33.70% ARGX, -0.64% lost a third of its value as the Amsterdam biotech said a late-stage trial did not meet primary or secondary endpoints. The Phase 3 study was of using efgartigimod subcutaneous in adults with pemphigus vulgaris and pemphigus foliaceus.
Stock markets looked ready to ease lower Tuesday morning after big gains earlier in the month. Zscaler stock fell back even with strong results in its fiscal first quarter.
In the world of investing, it's often the hidden gems that yield the most extraordinary returns. While Wall Street keeps a watchful eye on the giants, lesser-known stocks are quietly charting a course for explosive growth.
November 1, 2023 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of management will participate in several upcoming investor conferences in November: